FPWR maintains the latest clinical trial information so that you can stay abreast of trial opportunities. Some trials require in-person visits while others can be completed remotely. Some trials are testing new drugs while others are intervention (non-drug) or natural history studies. Details of...
Source: FPWR Blog
|
Published: September 9 2021 - 09:12 AM
Data from the PATH for PWS study, an ongoing natural history study of individuals with PWS sponsored by the Foundation for Prader-Willi Research, supports the benefits observed in the open-label study (C602) of DCCR. Analysis of trial data has shown a statistically significant reduction in...
Source: FPWR Blog
|
Published: September 9 2021 - 01:00 PM
Levo Therapeutic’s New Drug Application (NDA) for carbetocin as a treatment for PWS has been scheduled for a public meeting of the Psychopharmacologic Drugs Advisory Committee to be held on November 4th, 2021. The Food and Drug Administration (FDA) calls on Advisory Committees to provide...
Source: FPWR Blog
|
Published: September 9 2021 - 11:30 AM
Dr. Rachel Wevrick and her team have just published a new paper looking at the function of the protein encoded by the MAGEL2 gene, one of the genes in the PWS region of chromosome 15. This is the first-ever study to look at the first part of MAGEL2. The paper reveals new information about the form...
Source: FPWR Blog
|
Published: September 9 2021 - 09:00 AM
![PWS Registry Added 208 Participants In Past Year [INFOGRAPHIC]](https://www.fpwr.org/hubfs/Blog_Images/pws-registry-added-208-participants-in-past-year-feature.jpg)
The Global PWS Registry continues to grow and strengthen as a valuable resource and research tool for the PWS community. The Registry currently has 1,846 participants. Over the past 12 months (July 2020-July 2021), the Registry has grown by over 12% with 208 new participants! Individuals involved...
Source: FPWR Blog
|
Published: September 9 2021 - 01:00 PM
